As reported in MedPage Today by Kate Kneisel, adding the oncolytic virus talimogene laherparepvec (T-VEC) to the checkpoint inhibitor ipilimumab (Yervoy) in advanced unresectable melanoma yielded no economic benefit over ipilimumab alone, when assessment was limited to objective response, researchers said. In progression-free survival (PFS) analyses, the cost of talimogene laherparepvec plus ipilimumab ($494,983) was almost quadruple that of ipilimumab monotherapy ($132,950), according to Ivo Abraham, PhD, of the University of Arizona in Tucson. See Ms. Kneisel’s article for the rest of the details.
Ivo Abraham, PhD, of the University of Arizona
Source: MedPage Today